Recent Updates — MEDS

DataMEDS AI terminated its Second Amended and Restated Letter of Intent with EOS Technology Holdings, Scilex Holding Company, Datavault AI Inc., HealthBridge Advisors, Tollo Health, and REBOOT Health AI. The agreement contemplated acquiring intellectual property assets, expanding a PharmacyChain license, obtaining a controlling interest in Tollo Health, and establishing IP licensing arrangements in exchange for common stock. Termination was effective immediately due to market conditions, with no fees or obligations owed by DataMEDS. Existing exclusive licenses with REBOOT and Datavault remain in full force. The company operates in the healthcare sector, integrating health information technology, AI platforms, blockchain-enabled smart contracts, pharmacy services, and clinical molecular diagnostics.

DataMeds AI entered a non-binding Second Amended and Restated Letter of Intent to acquire Quality of Life Peace of Mind intellectual property from EOS Technology Holdings and Scilex, expand its license with Datavault AI, gain a controlling interest in Tollo Health (d/b/a Health Lives Here), and license technology from REBOOT Health AI. In exchange for these assets, DataMeds will issue common stock such that the sellers and partners are expected to own approximately 89.5% of the company on a fully diluted basis post-closing. The transaction is subject to definitive agreements, stockholder approval, Nasdaq compliance, and a liability reduction framework limiting indebtedness to $2 million. DataMeds operates in the healthcare technology sector, integrating artificial intelligence, blockchain, and telemedicine platforms with pharmacy distribution.

DataMeds AI, Inc. has received written notice from Nasdaq confirming it has regained compliance with Listing Rule 5550(b)(1), which requires a minimum stockholders’ equity of $2.5 million. The company previously received a deficiency letter on April 13, 2026, citing negative equity of $(12,447,801) and failure to meet alternative standards. While the company had already regained bid-price compliance in June 2026, this notice resolves the equity requirement. The filing notes that failure to evidence compliance upon filing its next periodic report may result in delisting proceedings. DataMeds AI operates as a healthcare technology company integrating Health IT platforms, pharmacy services, and artificial intelligence solutions.

DataMeds AI entered into an IP License Agreement with REBOOT Health AI, issuing 666,667 restricted common stock shares valued at $2 million as consideration for exclusive licensing rights within its GLP-1 weight management business. The company also settled approximately $18.7 million of debt and converted $1.5 million in vendor payables into equity since April 2026. These transactions increased stockholders' equity to over $2.5 million, allowing the company to claim compliance with Nasdaq Listing Rule 5550(b)(1) minimum equity requirements following a deficiency notice received in April 2026. The filing is pending formal confirmation from Nasdaq regarding continued listing status on The Nasdaq Capital Market. DataMeds AI operates in the health technology sector, focusing on digital solutions for weight management and patient care.

DataMEDS AI, Inc. entered into a settlement agreement with former sellers to resolve disputes regarding the Membership Interest Purchase Agreement. The company paid $450,000 total: $350,000 was allocated to repurchase and extinguish 364,099 shares of common stock, while $100,000 settled all other released claims. This transaction resulted in the extinguishment of approximately $19 million in liabilities on the consolidated balance sheet and increased stockholders' equity above $2.5 million. Additionally, the company licensed a care management platform from REBOOT Health AI, Inc., issuing 666,667 shares as consideration. DataMEDS AI operates in the healthcare technology sector, providing AI-driven solutions for medication adherence and patient engagement.

DataMEDS AI, Inc. entered into a settlement agreement on September 11, 2026, resolving litigation with Brian Norton and other selling holders regarding the Membership Interest Purchase Agreement. The company paid $450,000 in total consideration: $350,000 for the repurchase and extinguishment of 364,099 shares of common stock, and $100,000 to settle all other claims. Consequently, the company anticipates extinguishing approximately $19 million in liability from its consolidated balance sheet. The parties agreed to dismiss the Florida and Delaware actions with prejudice and exchange mutual releases. DataMEDS AI, Inc. operates in the healthcare technology industry, providing artificial intelligence solutions for pharmacy operations.